Michael S. Ching

Deletions of <i>NRXN1</i> (neurexin‐1) predispose to a wide spectrum of developmental disorders

Michael S. Ching, Yiping Shen, Wen‐Hann Tan et al. · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · 2010 · 308 citations · Full text

Brain Development, Genetics, Genetic Epidemiology +21

Precision therapy for epilepsy due to <i>KCNT1</i> mutations

Saul A. Mullen, Patrick W. Carney, Annie Roten et al. · Neurology · 2017 · 144 citations

The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain

Bronwyn Bebee, David McD Taylor, Elyssia Bourke et al. · The Medical Journal of Australia · 2021 · 53 citations · Full text

Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites

Michael S. Ching, Carolyn L. Blake, Hany Ghabrial et al. · Biochemical Pharmacology · 1995 · 52 citations

Biochemistry, Medicine, Secondary Metabolite +5

Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin

Victoria S. Haritos, Hany Ghabrial, Jorma T. Ahokas et al. · Pharmacogenetics · 2000 · 44 citations